Project portfolio management at novartis pharma

Strategies for best practice in benefit-risk management Using technology to enhance interactive connection with patients Providing valuable insight into the functioning of the PRAC Who are the most important stakeholders and how does the PRAC cooperate with them?

Project portfolio management at novartis pharma

In conversation with Pfizer's Erik Nordkamp Novartis hit by generic competition for Diovan in the UK as the drug's EU patents fall Actavis launches generic valsartan on the first day patent protection expired across a number of EU member states Actavis launched generic versions of various formulations of Novartis' blood pressure drug Diovan in the UK yesterday, on the first day that patent protection expired across a number of EU member states.

Supplementary protection certificates SPCs for Diovan in a number of European markets were due to expire in May this year, although in a number of EU countries Novartis was awarded six-month paediatric SPC extensions, extending protection to this month.

Patrick A. Baeuerle

The UK is among a number of other EU countries now clear for the launch of generics, so erosion of Diovan's sales is expected to gain pace, albeit offset by growth in Japan and some emerging markets, such as China, where it remains under patent.

The big hit is expected to come inhowever, when patents are lost in the US and a raft of other countries. Novartis has been trying to bolster the Diovan franchise with the launch of new line extensions, notably Co-Diovan valsartan and hydrochlorothiazide - itself facing patent expirations in a number of markets - and Exforge valsartan and amlodipine.

A triple combination pill based on aliskiren, amlodipine and hydrochlorothiazide - called Rasitrio - was recently backed for approval in the EU. Michael Cann, generics director at the company, said:A confluence of forces, driven by technology, is changing the landscape in healthcare and the pharmaceutical industry’s role within it.

Project portfolio management at novartis pharma

This intersection is creating unprecedented challenges and . Directory of California Biotech, Pharma & Life Sciences Companies. Alameda, CA: Analytical Chemistry and Microbiology. NMR and LCMS testing (GLP), GMP-NMR, Bioanalytical Testing (LCMS-MS), Antimicrobial Testing, Litigation Support and Consulting.

Actavis launched generic versions of various formulations of Novartis' blood pressure drug Diovan in the UK yesterday, on the first day that patent protection expired across a number of EU member states.

17th Annual Strategic Project & Portfolio Management for Pharma Bridge the Gaps between Analysis and Decision Making Processes, Enhance Agility, new Skills and Communication in a Complex Environment.

December 19, MPM Portfolio Company, Astute Medical, Forms Strategic Partnership with Bio-Techne. December 19, Novartis Signs Exclusive Option, Collaboration and License Agreement with MPM Portfolio Company Conatus Pharmaceuticals Inc.

Dr. K.

Project portfolio management at novartis pharma

Bangarurajan did his Degree in Pharmacy from Madras Medical College and M. Pharmacy from Banaras Hindu University, Varanasi in the Year and was awarded Ph.D.

by Tamil Nadu Dr. MGR Medical University in the Year

Short Guide to Pharmaceutical Portfolio Management – Red Sneakers Blog